fda warning letter glp-1 october 2025 Prescription by Algorithm: The Ethical and Legal Questions Behind Advertising FDA Targets Telehealth Compounded GLP-1

If it doesnt, we redirect without hesitation

Following high-profile reports in 2024 of an elevated risk of nonarteritic anterior ischemic optic neuropathy (NAION) in type 2 diabetes patients taking glucagonlike peptide-1 (GLP-1) receptor agonists seen at one facility (Massachusetts Eye and Ear), there remains a need to clarify the potential risk of ophthalmic complications from semaglutide exposure using multicenter data

And I was like, thats BS I know Im getting screwed. After experiencing exactly what I described she didnt just build this much needed tool, she started rotating providers to go through the whole painful process so that you dont have to